期刊文献+

甲基泼尼松龙脉冲治疗Graves’眼病 被引量:2

Pulse treatment with methylprednisolone on Graves' ophthalmopathy
下载PDF
导出
摘要 目的评价大剂量甲基泼尼松龙脉冲治疗Graves’眼病的疗效。方法采用大剂量甲基泼尼松龙脉冲治疗Graves’眼病12例。予甲基泼尼松龙10~15mg/(kg·d)静脉滴注,隔日重复1次;2周后重复以上治疗方法;然后甲基泼尼松龙剂量减半后同上述方法再治疗4次,整个疗程2个月。结果12例患者经治疗后眼部症状均得到一定改善,显效率达58%。结论大剂量甲基泼尼松龙脉冲治疗Graves’眼病有效且安全,尤其对病程短、病变活动程度较高的患者疗效好。 Objective It is to investigate the clinical effect of pulse treatment with high-dose methylprednisolone on Graves' ophthalmopathy. Methods Twelve patients with Graves' ophthalmopathy were taken high-dose methylprednisolone pulse therapy by intravenous infusing at the dose of 10 - 15 mg/(kg·d) and then repeated every two day. This treatment mentioned above was taken again after two weeks. In the second months, the above method was used four times at the halved dose of methylprednisolone. The treatment course was 2 months. Results Eye symptoms of twelve patients were im- proved at a certain degree after treatment with a significant effective rate of 58%. Conclusion The pulse treatment of Graves' ophthalmopathy by high-dose methylprednisolone is effective and safe, and it especially has good curative effect for patients who have short disease course and have higher levels of disease activity.
作者 刘新亮
出处 《现代中西医结合杂志》 CAS 2010年第12期1446-1447,1449,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 Graves’眼病 甲基泼尼松龙 脉冲疗法 Graves' ophthalmopathy methylprednisolone pulse treatment
  • 相关文献

参考文献10

  • 1Hemant Parmar,Mohannad Ibrahim.Extrathyroidal manifestations of thyroid disease:thyroid ophthalmopathy[J].Neuroimag Clin N Am,2008,18(3):527-536.
  • 2Rose JG Jr,Burkat CN,Boxrud CA.Diagnosis and management of thyroid orbitopathy[J].Otolaryngol Clin North Am,2005,38(5):1043-1074.
  • 3Shanli Tsui,Vibha Naik,Neil Hoa,et al.Evidence for an association between thyroid-stimulation hormone and insulin-like growth factor 1 receptors:A tale of two antigens implicated in Graves'disease[J].The Journal of Immunology,2008,181(6):4397-4405.
  • 4Andrew G.Gianoukakisa 8 Terry J.Smithb.Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy[J].Curr Opin Endocrinol Diabetes Obes,2008,15(5):446-452.
  • 5Kim Nancy,Hatton Mark P.The role of genetics in Graves' disease and thyroid orbitopathy[J].Seminars in Ophthalmology,2008,23(1):67-72.
  • 6Kulig G,Andrysiak-Mamos E,Sowińska-Przepiera E,et al.Quality of life assessment in patients with Graves' disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy[J].Endokrynol Pol,2009,60(3):158-165.
  • 7Sánchez-Ortiga R,Moreno-Pérez O,González-Sánchez V,et al.Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone:a comparison of two dosing regimens[J].Endocrinol Nutr,2009,56(3):118-122.
  • 8Stiebel-Kalish H,Robenshtok E,Hasanreisoglu M,et al.Treatment modalities for Graves'ophthalmopathy:systematic review and metaanalysis[J].J Clin Endocrinol Metab,2009,94(8):2708-2716.
  • 9Bao Nguyen,Bamini Gopinath,Junichi Tani,et al.Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves'ophthalmopathy[J].Autoimmunity,2008,41(5):372-376.
  • 10Mario Salvi,Guia Vannucchi,Irene Campi,et al.Treatment of Graves'disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab:an open study[J].European Journal of Endocrinology,2007,156(1):33-40.

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部